

1 **Eliminating mother-to-child transmission of HIV in**
2 **Tanzania calls for efforts to address factors associated**
3 **with a low confirmatory test**

4

5

6

7 **Baraka M. Morris^{1*}, Mukome Nyamhagata², Edith Tarimo¹, Bruno Sunguya¹**

8

9 ¹ Muhimbili University of Health and Allied Sciences, P.O. Box 65001, Dar es salaam,

10 Tanzania

11 ² Ministry of Health, P.O. Box 743, Dodoma, Tanzania

12

13 ***Corresponding author**

14 **Email: bamalaki@yahoo.com (BMM)**

15

16

17

18

19

20 **Abstract**

21 **Background:** Option B+ approach for prevention of mother-to-child transmission
22 (PMTCT) has demonstrated the potential to eliminate pediatric HIV infections. Its success
23 depends on early infant diagnosis (EID) of HIV among the exposed infants within the first
24 6 weeks, and a subsequent confirmatory HIV test at the 18th month. However, most mothers
25 enrolled in the PMTCT-option B+ cascade of services in Tanzania do not turn-up for such
26 confirmatory tests. We examined factors associated with the turning-up of mother-baby
27 pairs on the PMTCT program for confirmatory HIV testing 18 months post-delivery in
28 Tanzania.

29 **Methods:** This study utilized longitudinal data collected between 2015 and 2017 from 751
30 mother-baby pairs enrolled in the PMTCT- Option B+ approach in 79 health facilities from
31 the 12 regions of Tanzania-mainland. Analysis was conducted using descriptive statistics
32 to characterize the proportion of mother-baby pairs turning up for a confirmatory test and
33 logistic regression analysis to examine factors associated with turning up for a
34 confirmatory HIV testing at the 18th month.

35 **Results:** A total of 751 mother-baby records were observed only and 44.2% (95% CI: 40.7
36 – 47.8) of them received the HIV confirmatory test at 18 months. Mothers aged 25 years
37 or above (adults' mothers) were 1.44 more likely to turn up for confirmatory HIV-testing
38 than young mothers; mothers with partners tested for HIV were 1.74 more likely to have
39 confirmatory HIV-testing compared with partners not tested for HIV; newly HIV-positive
40 mothers diagnosed on enrolment were 28% less likely to turn up their babies for
41 confirmatory HIV-testing compared to known HIV-positive mothers; mothers with
42 treatment supporters were 1.58 more likely to receive confirmatory HIV-testing compared

43 to mothers without one, and mothers with babies whose DBS-PCR-1 was collected were
44 3.61 more likely to have confirmatory HIV-testing than those who didn't collect DBS-
45 PCR-1.

46 **Conclusion:** This study reveals that the turn-up for confirmatory HIV testing at 18 months
47 among mother-baby pairs enrolled in the Option B+ approach is still low in Tanzania. This
48 turn-up is associated with low maternal age, having a male partner who has not tested for
49 HIV, lack of experience with HIV services, lack of treatment supporters, and failure to take
50 the first DBS-PCR HIV test within the first two months post-delivery.

51

52 **Introduction**

53 The overall risk of HIV transmission from mother-to-child without any intervention ranges
54 from 20% to 45% (Ref). Such unprecedented risk can be ameliorated with a successful
55 implementation of preventing mother-to-child transmission (PMTCT) interventions that
56 includes screening and treatment of both mothers and their newborn. [1-3] Remarkable
57 efforts have been made in scaling up PMTCT services globally. Such efforts have resulted
58 in marked improvement in PMTCT among countries with a heavy burden of HIV/AIDS.[4]
59 Nevertheless, despite marked efforts and investment, the unprecedented burden of new
60 infections still occurs among HIV-exposed newborns globally—Tanzania is no exception.
61 The World Health Organization (WHO) recommended the adoption of universal
62 antiretroviral treatment or Option B+, as the preferred PMTCT approach in LMICs with
63 high HIV prevalence, high fertility, and extended breastfeeding.[2, 5] Under this plan, all
64 women who test HIV positive are enrolled in lifelong ART soon after HIV diagnosis,

65 regardless of their CD4 count, or HIV clinical stage. The implementation of the Option B+
66 program requires women and their infants to access HIV care including a PMTCT cascade
67 of HIV prevention services for two years post-delivery.[6] The Option B+ cascade of
68 interventions requires the exposed children to undertake a confirmatory HIV test at 18
69 months of age to determine whether they are infected. If the child is infected, both the
70 mother and her child are transferred to Care Treatment Clinics (CTC).[5-7]

71

72

73 The adoption and implementation of Option B+ in Tanzania still face several challenges
74 similar to many other sub-Saharan countries. Studies reveal that a significant proportion of
75 women decline the PMTCT service outright, while another group silently defaults from
76 care.[8, 9] The proportion of infants who receive confirmatory HIV tests is also very low.
77 Only 34.6% of babies from HIV-infected mothers are brought for confirmatory HIV testing
78 at 18 months of age.[10] Low turn-up for confirmatory HIV testing denies the opportunity
79 for early diagnosis and treatment among children who might have been infected during
80 breastfeeding. Findings show that most of these undiagnosed children are likely to die
81 before their second birthday if they do not receive treatment.[2, 7, 11]

82

83 Evidence on the reasons and causes for low turn-up for confirmatory tests remains
84 inconclusive and varies in Tanzania like in other countries. Thus, this study investigated
85 factors associated with poor turn-up for confirmatory HIV testing at 18 months of age
86 among mother-baby pairs enrolled in the PMTCT Option B+ cascade in Tanzania.

87

88 **Materials and Methods**

89 **Study Design and Population**

90 This secondary analysis study used data from a cohort of mother-baby pairs who received
91 PMTCT care in 79 health facilities in 12 selected regions of Tanzania between 2015-2017.
92 Tanzania approved the National Guidelines for the implementation of Option B+ in
93 2013. According to this guideline, all pregnant mothers who tested HIV positive were
94 counseled and enrolled in the Option B+ approach where they were monitored from their
95 first antenatal clinic visit until their babies were two years old.[12, 13] Data was collected
96 to monitor and evaluate the adherence to treatment among mother-baby pairs enrolled in
97 the Option B + approach of PMTCT.

98

99 **Sample Size and sampling**

100 Multistage random sampling was used to select 79 health facilities in the 12 regions
101 of Tanzania mainland for the primary study. In these health facilities, a total of 4,738
102 HIV-positive mother-baby pairs were enrolled in the Option B+ program from 2015
103 to 2017. In the current study, only 751 HIV-positive mother-baby pairs were analyzed
104 owing to the completeness of their medical records.

105

106 **Variables and measures**

107 The outcome variable was the infant's confirmed HIV status at the 18th month of age. The
108 outcome responses were categorical and measured using a nominal scale (dichotomous -

109 Yes/No), where “Yes” was for mother-baby pairs who turned for confirmatory HIV testing
110 and “No” was for mother-baby pairs who did not turn for confirmatory HIV testing (Lost
111 to Follow up). This did not include babies who died in the course of 18 months.

112 Independent variables included eight variables. These are: Maternal age groups defined
113 based on the WHO age groups where mothers aged 24 years and less form the young group
114 and those aged 25 years and above from the adult group (2) Gravidity defined as the number
115 of times that a woman has been pregnant. Gravidity was classified into two categories, the
116 first category for mothers in their first & second pregnancies (G1-G2) and the second
117 category for mothers with more than two pregnancies (G3 – max). (3) Gestational age is
118 the measure (usually in weeks) of the age of a pregnancy. Normally, the gestation age is
119 grouped into three groups (trimesters). However, the WHO recommends women start
120 antenatal care in their first trimester. In this study, the gestation age was grouped into two
121 categories, the first category for mothers who were enrolled in their 1st trimesters and the
122 second category for mothers who enrolled in the 2nd and 3rd trimesters. (4) Live with Partner
123 (marital status) measured as a nominal categorical (dichotomous -Yes/No) variable where
124 “Yes” was for married and cohabited mothers and “No” was for Single, divorced, and
125 widowed mothers. (5) Partner tested measured as a categorical variable using a nominal
126 scale (dichotomous -Yes/No), where “Yes” was for mothers with a partner who has tested
127 for HIV and “No” for mothers with a partner who has not tested for HIV (6) Maternal HIV
128 status at enrolment measured as a nominal categorical variable with two groups. The first
129 group was for mothers whose HIV status was already known as HIV positive and the
130 second group was for mothers who were newly diagnosed as HIV positive at enrollment in
131 antenatal care (Known HIV +ve and New HIV +ve). (7) Presence of treatment supporters

132 was measured dichotomously using a nominal scale. “Yes” was for mothers with treatment
133 supporter(s) and “No” was for mothers without treatment supporter(s). (8) Lastly,
134 Collection of the first dry blood smear (DBS-PCR-1) within the first two months post-
135 delivery. Option B+ PMTCT cascade requires HIV-exposed infants to have their first HIV
136 test within 2 months of age for early HIV diagnosis. For each mother-baby pair it was
137 recorded whether DBS-PCR-1 was collected or not and hence, was measured
138 dichotomously (Yes/No) using a nominal scale.

139 **Loss to Follow-up**

140 Loss to follow-up was one of the child’s final status at the last visit. Likewise, this was one
141 of the observations for not showing up for confirmatory HIV testing at the 18th month age
142 of the baby. However, in this study, we did not analyze the child's last status, because child
143 status is determined at the end of two years.

144

145 **Data Analysis**

146 The analysis focused on examining the upshots of Option B+ on the compliance to services
147 among mother-baby pairs enrolled in the PMTCT program in Tanzania mainland. Factors
148 associated with poor turn-up for confirmatory HIV testing at 18 months of infant age
149 among these mother-baby pairs were analyzed as well. These factors were placed into four
150 groups namely: maternal social-demographic characteristics (maternal age, gravidity,
151 gestation age at enrolment, and live with a partner), experience with HIV services on
152 enrolment (maternal HIV status), partner involvement on turn-up for confirmatory HIV
153 testing (Partner tested), and presence of treatment supporters (treatment supporter). The

154 analysis examined whether these factors were associated with turn-up for confirmatory
155 HIV testing.
156 Data were cleaned and analyzed using the STATA version 15th software package.
157 Measures of central tendency (frequencies, means, medians, and standard deviations)
158 described the socio-demographic characteristics of study participants (HIV-positive
159 mother-baby pairs). A chi-square test of independence was used for the bivariate analysis
160 of the relationships between outcomes and independent categorical variables. A p-value of
161 0.05 or less was used to determine the significance of the association between predictors
162 and outcome variables. Then the multivariate analysis using multinomial logistic
163 regression analysis was used to determine associations and ascertain the effect of
164 confounders. The backward elimination method was used to determine the final model.
165 First, the model contained all variables that showed significant association with the
166 outcome variable during the bivariate analysis. The least significant variable (the one with
167 the highest p-value) was removed from the model. The elimination continued until the
168 stopping rule was reached. The stopping rule was when all remaining variables had a
169 significant p-value (P=0.05).

170 **Ethical Consideration**

171 Ethical clearance for the PMTCT project was obtained from the National Institution of
172 Medical Research (NIMR) and the permission to use mother-baby pairs PMTCT Option
173 B+ cascade data was received from the Ministry of Health, Community Development,
174 Gender, Elderly, and Children, through the PMTCT coordination unit. Informed consent
175 was waived because this was purely secondary data and hence, we did not interact with the

176 subjects. Confidentiality of participants in the data was highly maintained and special
177 identification numbers were used to ensure anonymity.

178

179

180 **Results**

181 **General characteristics**

182 The mean age of mothers included in this analysis was 28.9 (SD = 5.8) years. The mean
183 number of pregnancies (gravidity) was 3 ± 2 and the mean gestation age at enrolment was
184 19.1 ± 6.2 weeks. A total of 502 (78.9%) of 636 mothers who indicated their marital status
185 were living with their partners (i.e. married or cohabited).

186

187 **Baseline HIV Testing Characteristics of Mother-Baby Pairs**

188 Of the 751 mother-baby records observed, 733 (97.6%, 95% CI: 96.2 – 98.5) had DBS1
189 collected by 2 months of age but only 332 (44.2%, 95% CI: 40.7 – 47.8) mother-baby pairs
190 received the HIV confirmatory test at 18 months. More than half of 429 (57.1%, 95% CI:
191 53.5 – 60.6) mothers were newly HIV positive and diagnosed upon enrolment; less than a
192 quarter of 157 (20.9%, 95% CI: 18.1 – 24) mothers had tested partners; and the majority
193 644 (85.5%, 95% CI: 83.1 – 88.1) of mothers had treatment supporters. (Table 1)

194

195 A chi-square test of independence was used to assess the relationship between independent
196 variables and mother-baby pairs HIV confirmatory testing at the 18 months of age

197 (confirmed HIV testing). There was a significant relationship between the following
 198 variables and confirmed HIV testing: maternal age group $X^2(1, N = 751) = 6.57, p = 0.01$;
 199 gravidity $X^2(1, N = 751) = 6.96, p = 0.008$; maternal HIV status at enrollment $X^2(1, N =$
 200 $751) = 4.73, p = 0.03$; partner being tested $X^2(1, N = 751) = 7.94, p = 0.005$; collection
 201 dried blood spot for *HIV-1* PCR tested $X^2(1, N = 751) = 5.67, p = 0.02$; and presence of
 202 treatment supporter tested $X^2(1, N = 751) = 4.69, p = 0.03$. There was not a significant
 203 relationship between the following variables and confirmed HIV testing: gestation age
 204 group at enrolment $X^2(1, N = 751) = 3.60, p = 0.06$ and marital status (Live with a partner)
 205 $X^2(1, N = 636) = 0.06, p = 0.81$. Table 1 below summarizes the results of the descriptive
 206 analysis of the baseline HIV testing characteristics of mother-baby pairs

207 **Table 1: The Baseline HIV Testing Characteristics of the 751 Mother-Baby Pairs**
 208 **enrolled in the PMTCT cascade in selected health facilities between 2015 and 2017**

Variables	Frequency (%)	95% Conf. Interv	Confirmed HIV - Testing		P-Value	
			No (%)	Yes (%)		
Maternal Age Group	Young (10 – 24)	188 (25)	22.1 – 28.2	120 (63.8)	68 (36.2)	0.010
	Adults (25 – max)	563 (75)	71.7 – 77.9	299 (53.2)	264 (46.9)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Gravidity Groups	G1 – G2	286 (38.1)	34.7 – 41.6	177 (61.9)	109 (38.1)	0.008
	G3 - Max	465 (61.9)	58.4 – 65.3	242 (52.0)	223 (48.0)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Gestation Age Group	1 st Trimester	138 (18.4)	15.8 – 21.3	87 (63.0)	51 (37.0)	0.058
	2 nd & 3 rd Trimester	613 (81.6)	78.7 – 84.2	332 (54.2)	281 (45.8)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Live with Partner	No	134 (21.1)	18.1 – 24.4	76 (56.7)	58 (43.3)	0.814
	Yes	502 (78.9)	75.6 – 81.9	279 (55.6)	223 (44.4)	
	Total	636 (100)		355 (55.8)	281 (44.2)	
Maternal HIV status on Enrolment	Know HIV +ve	322 (42.9)	39.4 – 46.5	165 (51.2)	157 (48.8)	0.030
	New HIV +ve	429 (57.1)	53.5 – 60.6	254 (59.2)	175 (40.8)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Partner Tested	No	594 (79.1)	76 – 81.8	347 (58.4)	247 (41.6)	0.005
	Yes	157 (20.9)	18.1 – 24	72 (45.9)	85 (54.1)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
DBS1 Collected	No	18 (2.4)	1.5 – 3.8	15 (83.3)	3 (16.7)	0.017
	Yes	733 (97.6)	96.2 – 98.5	404 (55.1)	329 (44.9)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Treatment Supporter	No	107 (14.3)	11.9 – 16.9	70 (65.4)	37 (34.6)	0.030
	Yes	644 (85.7)	83.1 – 88.1	349 (54.2)	295 (45.8)	
	Total	751 (100)		419 (55.8)	332 (44.2)	

Confirmed HIV Testing	No	419 (55.8)	52.2 – 59.3			
	Yes	332 (44.2)	40.7 – 47.8			
	Total	751 (100)				

209

210

211 **Factors associated with confirmatory HIV testing among**
212 **exposed children at 18 months of age**

213 All factors that were statistically significantly associated with the dependent variable were
214 entered into the regression analysis. The binary logistic regression was conducted to
215 provide unadjusted odds ratios. Then multivariate logistic regression was used to obtain an
216 adjusted odds ratio (OR). During the backward elimination method to determine the final
217 model, gravidity and gestation age were not statistically significant and were eliminated
218 consecutively (Table 2).

219 The results of multiple regression analysis of the factors included in the final model were:
220 Maternal age group adults' mothers were 1.44 more likely to receive confirmatory HIV-
221 testing for their babies than young mothers (Maternal age group AOR=1.44 and p =0.04).
222 Mothers with partners who tested for HIV were 1.74 more times likely to have
223 confirmatory HIV testing than those with partners not tested for HIV (Partner tested
224 AOR=1.74 and p=0.003). New HIV-positive mothers diagnosed on enrolment were 0.72
225 less likely to turn up their babies for confirmatory HIV-testing than known HIV-positive
226 mothers (Maternal HIV status at enrolment AOR=0.72 and p=0.033); mothers with
227 treatment supporters were 1.58 times more likely to receive confirmatory HIV-testing than
228 mothers without treatment supporters (Treatment supporter AOR=1.58 and p=0.041), and

229 finally, mothers with babies whose DBS1 was collected were 3.61 more likely to have
230 confirmatory HIV-testing (DBS1 collection AOR=3.61 and p=0.048).

231

232 **Table 2: Logistic regression analysis of factors associated with turn up for**
233 **confirmatory among HIV-positive mother-baby pairs who were enrolled in PMTCT**
234 **cascade in selected health facilities between 2015 and 2017.**

Factor	OR	P-Value	95% CI	AOR	P-Value	95% CI
Maternal Age Group	1.56	0.011	1.11 – 2.19	1.44	0.040	1.02 – 2.04
Partner tested	1.66	0.005	1.16 – 2.36	1.74	0.003	1.21 – 2.50
Maternal HIV Status	0.72	0.030	0.54 – 0.97	0.72	0.033	0.53 – 0.97
Treatment Supporter	1.60	0.031	1.04 – 2.45	1.58	0.041	1.02 – 2.46
DBS1 Collected	4.07	0.027	1.17 – 14.18	3.61	0.048	1.01 – 12.84

235

236

237 **Discussion**

238 This study provides a picture of the implementation of Option B+ in Tanzania mainly
239 focusing on early infant diagnosis (EID) of HIV among exposed infants. Confirmatory HIV
240 testing is a very important part of EID to ensure that all affected infants are identified and
241 enrolled in treatment. In this study 44.2% of mothers enrolled in Option B+ turned in their
242 babies for confirmatory testing. The study revealed that: Maternal age - adult mothers were
243 more likely to take their babies for confirmatory HIV testing than young mothers, mothers
244 with a tested partner were more likely to take their babies for confirmatory HIV testing
245 than mothers with partners who have not been tested, newly diagnosed mothers were less

246 likely to take their babies for confirmatory HIV testing than mothers who knew of their
247 HIV status prior to the enrolment (Known HIV positive), mothers with treatment
248 supporters were more likely to take their babies for confirmatory HIV testing than mothers
249 without treatment supporters, and mothers who brought their babies for DBS-PCR-1
250 collection were more like to take for confirmatory HIV test at the 18-month post-delivery
251 than those mothers who did not bring their babies for DBS-PCR-1 collection.

252 Lost follow-up is one of the major problems that affect the uptake of confirmatory HIV
253 testing.[14] The implementation of option B+ in Tanzania has remarkably increased the
254 uptake of confirmatory HIV testing at 18 months of age. However, most mothers are still
255 lost to follow-up after the first two months post-delivery. This study showed that 44% of
256 mothers brought their babies for confirmatory HIV testing at the 18th month, which is
257 higher than findings of past studies in Tanzania found only 34.6% of mothers brought their
258 babies to the test.[10, 15] Despite the fact that DBS-CPR 1 collection has been associated
259 with the increase in the uptake of confirmatory HIV testing; still more than 50% of mothers
260 who came for DBS-PCR 1 lost to follow up. The finding is consistent with findings of past
261 studies in Northern Tanzania, which revealed a high loss to follow-up after the first two
262 months post-delivery as one of the setbacks in the implementation of Option B+.[15, 16]
263 Does this have to do with insufficient knowledge about the Option B+ cascade of services
264 until after 18 months? Probably they thought that the DBS-PCR 1 test results were
265 confirmatory and there was no need for another test. Mothers of babies with HIV-negative
266 DBS-PCR 1 results need intensified counseling and close follow-up just like those who
267 test Positive. This will ensure that mother-baby pairs remain in treatment and babies remain
268 HIV-free until they graduate at 18 months.

269

270 Being an adult mother and experienced with PMTCT has been found to increase
271 compliance to Option B+. Adult mothers (aged 25 years and above) were more likely to
272 turn up for confirmatory HIV tests at their babies 18 months of age HIV than young
273 mothers (aged less than 25). The majority of the women in Tanzania have their first
274 delivery in their youth age.[17] Hence, by the time they reach adulthood age (25 years),
275 they have experienced reproductive health services and might have been exposed to
276 PMTCT services thus knowing the importance of adherence to services. Likewise, mothers
277 who were newly HIV diagnosed (less experienced with PMTCT) were less likely to turn
278 up for confirmatory HIV test at the 18-month post-delivery than mothers who knew their
279 HIV status before enrolment to antenatal care (experienced with PMTCT). Studies done in
280 sub-Saharan Africa have indicated poor adherence to Option B+ among young and newly
281 HIV-diagnosed mothers.^{3,4} Poor adherence among mothers enrolled in Option B+ has been
282 found to be associated with a lack of experience with PMTCT services, short time to
283 process and accept results, denial of the test results, fear of committing to a life-long
284 treatment regimen, feeling of shame, and stigma.[16, 18]

285 One of the unique findings in this study is that having a partner who has been tested for
286 HIV is very important for compliance with Option B+ regardless of marital status. While
287 marital status had no association with mothers turning in their babies for confirmatory HIV
288 testing; mothers who had their partners tested for HIV are more likely to turn up for
289 confirmatory HIV tests at their babies 18 months of age. This is contrary to recent studies
290 in sub-Saharan Africa, which revealed that married mothers were more likely to adhere to
291 option B+ than unmarried mothers. [19, 20] Awareness of the partner's HIV status has been

292 associated with compliance with Option B+ services. Studies in Malawi, Ethiopia, and
293 Kenya revealed that mothers who know the HIV status of their partners are more likely to
294 remain in Option B+ care than those who did not know[21]. The finding from this study
295 goes the extra mile as it indicates mothers who know that their partners have tested for HIV
296 regardless of knowledge of their HIV status have an impact on the compliance to Option
297 B+ care. Unfortunately, in this study, less than a quarter of mothers involved in the analysis
298 had their partners tested. The calls for more effort to educate male partners on the
299 importance of HIV testing.

300 The presence of treatment supporters improves mothers' compliance to Option B+ cascade
301 of services. The majority of mothers involved in this study had a treatment supporter. These
302 findings support studies showing that treatment supporters increase compliance with
303 Option B+.[16, 21-24] A treatment supporter can be a couple, a sibling, a relative, or a
304 friend who a mother has selected to assist. The use of treatment supporters has been a
305 successful technique used in patients with chronic conditions that require long-term course
306 treatment. For instance, treatment supporters have been useful for many years in Tanzania
307 to ensure patients' adherence to the tuberculosis treatment regime.[25, 26] The study
308 conducted Kilimanjaro region on the predictors of postpartum HIV care engagement
309 among women in the PMTCT program, suggested strengthening the social support network
310 system by engaging treatment supporters in HIV care. [13, 16, 18, 27, 28] Therefore,
311 findings from this study cement the importance of engaging treatment supporters not only
312 in engaging mothers to care but also to ensure that their babies receive the

313 **Limitation**

314 This study-employed data from the ministry of health management information system (HMIS)
315 and the PMTCT cascade survey data collected from 80 health facilities. The following limitations
316 were highlighted in this study: Data quality: only 751 of 4738 data collected were complete. This
317 might have affected or influenced some of the results. There is a need to train health workers on
318 the importance of proper documentation, constant supervision, and employ more health workers to
319 cover the shortage. Likewise, these findings are from the analysis of secondary data that were
320 primarily collected from the randomly selected health facilities for routine monitoring activities of
321 PMTCT services. Therefore, it is difficult to know exactly how well the data collection process
322 was done.

323

324 **Conclusion**

325 This study has found that the turn-up for confirmatory HIV testing at 18 months among
326 mother-baby pairs enrolled in the Option B+ approach is still low in Tanzania. More than
327 half of mothers lost to follow-up after the first two months post-delivery. This low turn-up
328 for the confirmatory HIV testing among mother-baby pairs enrolled in the Option B+
329 approach is associated with low maternal age (young mothers), the low uptake of HIV
330 testing among male partners (having a male partner who has not tested for HIV), being a
331 newly diagnosed HIV mother (lack of experience to HIV services), lack of treatment
332 supporters, and failure to take the first DBS-PCR HIV test within the first two months post-
333 delivery. These factors have to be addressed in the Option B+ implementation guidelines
334 in order to increase the retention of mother-baby pairs into the Option+ B cascade of
335 services.

336 **Recommendations for future directions**

337 The study recommends the following: Post-HIV testing counseling sessions among young mothers
338 (mothers under 25 years of age) and newly HIV-diagnosed mothers be intensified; male partner
339 involvement in reproductive services, couple counseling, and the importance of HIV result
340 disclosure should be enhanced; and further studies be done to identify the best modalities of
341 identifying, integrating and utilizing treatment supporters who will assist HIV infected mother to
342 comply Option B+ cascade,
343

344 **Reference:**

- 345 1. UNAIDS U. Countdown to ZERO: global plan towards the elimination of new HIV
346 infections among children by 2015 and keeping their mother alive: UNAIDS; 2011.
- 347 2. UNAIDS. 2015 progress report on the global plan towards the elimination of new
348 HIV infections among children and keeping their mothers alive. 2015.
- 349 3. Muyunda B, Musonda P, Mee P, Todd J, Michelo C. Effectiveness of lifelong ART
350 (Option B+) in the prevention of mother-to-child transmission of HIV programme in
351 Zambia: observations based on routinely collected health data. *Frontiers in public health*.
352 2020;7:401.
- 353 4. Kak L, Chitsike I, Luo C, Rollins N. Prevention of mother-to-child transmission of
354 HIV/AIDS programmes. Opportunities for Africa's newborns: Practical data, policy and
355 programmatic support for newborn care in Africa: WHO; 2011. p. 113-26.
- 356 5. AVERT. Prevention of mother-to-child transmission (PMTCT) of HIV 2017
357 [cited 2018]. Available from: [https://www.avert.org/professionals/hiv-](https://www.avert.org/professionals/hiv-programming/prevention/prevention-mother-child)
358 [programming/prevention/prevention-mother-child](https://www.avert.org/professionals/hiv-programming/prevention/prevention-mother-child).

- 359 6. Gamell A, Luwanda LB, Kalinjuma AV, Samson L, Ntamatungiro AJ, Weisser M,
360 et al. Prevention of mother-to-child transmission of HIV Option B+ cascade in rural
361 Tanzania: The One Stop Clinic model. *PloS one*. 2017;12(7):e0181096.
- 362 7. MoHCDGEC. Tanzania Elimination of Mother to Child Transmission of HIV
363 Strategic Plan II 2018 – 2021. Dar es Salaam: MoHCDGEC; 2017.
- 364 8. Kalua T, Tippett Barr B, van Oosterhout J, Mbori-Ngacha D, Schouten E, Gupta S,
365 et al. Lessons Learned From Option B+ in the Evolution Toward “Test and Start” From
366 Malawi, Cameroon, and the United Republic of Tanzania. *Acquir Immune Defic Syndr*.
367 2017;75(Suppl 1):S43-S50.
- 368 9. McLean E, Renju J, Wamoyi J, Bukonya D, Ddaaki W, Church K, et al. ‘I wanted
369 to safeguard the baby’: a qualitative study to understand the experiences of Option B+ for
370 pregnant women and the potential implications for ‘test-and-treat’ in four sub-Saharan
371 African settings. *Sex Transm Infect*. 2017;93(Suppl 3).
- 372 10. Samson S, Mpembeni RN, Njau PF, Kishimba RS. Uptake of early infant diagnosis
373 (EID) at six weeks after cessation of breastfeeding among HIV exposed children: A cross
374 sectional survey at six high volume health facilities in Iringa, Tanzania. *Journal of*
375 *Interventional Epidemiology and Public Health*. 2018;1(10).
- 376 11. MoHSW T. National Guidelines for Comprehensive Care Services for Prevention
377 of Mother-to-Child Transmission of HIV and Keeping Mothers Alive. In: Programme NP,
378 editor. Dar es Salaam, Tanzania: MoHSW, Tanzania; 2013.
- 379 12. UNAIDS. 2015 PROGRESS REPORT ON THE GLOBAL PLAN
380 towards the elimination of new HIV infections among children and keeping their mothers
381 alive. 2015.

- 382 13. Atanga P. Retention-in-Care, Adherence and Treatment outcomes in a cohort of
383 HIV- positive pregnant and breastfeeding women enrolled in a pilot project implementing
384 “Option B+” in Cameroon.: Medical Centre of the University of Munich (LMU); 2016.
- 385 14. Gumede-Moyo S, Filteau S, Munthali T, Todd J, Musonda P. Implementation
386 effectiveness of revised (post-2010) World Health Organization guidelines on prevention
387 of mother-to-child transmission of HIV using routinely collected data in sub-Saharan
388 Africa: a systematic literature review. *Medicine*. 2017;96(40).
- 389 15. Cichowitz C, Mazuguni F, Minja L, Njau P, Antelman G, Ngocho J, et al.
390 Vulnerable at each step in the PMTCT care cascade: high loss to follow up during
391 pregnancy and the postpartum period in Tanzania. *AIDS and Behavior*. 2019;23(7):1824-
392 32.
- 393 16. Mazuguni F, Mwaikugile B, Cichowitz C, Watt MH, Mwanamsangu A, Mmbaga
394 BT, et al. Unpacking loss to follow-up among HIV-infected women initiated on option B+
395 in Northern Tanzania: a retrospective chart review. *EA Health Research Journal*.
396 2019;3(1):6-15.
- 397 17. Ministry of Health CD G, Elderly, Children MoHMZ NBoS. Tanzania
398 demographic and health survey and malaria indicator survey (TDHS-MIS) 2015–16.
399 MoHCDGEC, MoH, NBS, OCGS, and ICF Dar es Salaam, Tanzania, and Rockville,
400 Maryland, USA. 2016.
- 401 18. Watt MH, Cichowitz C, Kisigo G, Minja L, Knettel BA, Knippler ET, et al.
402 Predictors of postpartum HIV care engagement for women enrolled in prevention of
403 mother-to-child transmission (PMTCT) programs in Tanzania. *AIDS care*.
404 2019;31(6):687-98.

- 405 19. Lencha M. Adherence to option B+ and associated factors among pregnant women
406 on PMTCT Services at Public Health Facilities of east Shawa zone, Oromia, Ethiopia. J
407 Womens Health Reprod Med. 2018;2(1):2.
- 408 20. Flax VL, Hamela G, Mofolo I, Hosseinipour MC, Hoffman IF, Maman S. Factors
409 influencing postnatal Option B+ participation and breastfeeding duration among HIV-
410 positive women in Lilongwe District, Malawi: A qualitative study. PloS one.
411 2017;12(4):e0175590.
- 412 21. Asefa EY, Dirirsa DE. Level of Good Adherence on Option B+ PMTCT and
413 Associated Factors Among HIV Positive Pregnant and Lactating Mothers in Public Health
414 Facilities of Ilu Abba Bor and Buno Bedele Zones, Oromia Regional State, Southwestern
415 Ethiopia, 2018. HIV/AIDS (Auckland, NZ). 2020;12:789.
- 416 22. Yeshialem Asefa E, Edosa Dirirsa D. Level of Good Adherence on Option B+
417 PMTCT and Associated Factors Among HIV Positive Pregnant and Lactating Mothers in
418 Public Health Facilities of Ilu Abba Bor and Buno Bedele Zones, Oromia Regional State,
419 Southwestern Ethiopia, 2018. HIV AIDS (Auckl). 2020;12:789-98. doi:
420 10.2147/HIV.S283184. PubMed PMID: 33273864.
- 421 23. Wondimu F, Yetwale F, Admassu E, Binu W, Bulto GA, Lake G, et al. Adherence
422 to Option B+ Care for the Prevention of Mother-to-Child Transmission Among Pregnant
423 Women in Ethiopia. HIV/AIDS (Auckland, NZ). 2020;12:769.
- 424 24. Kisigo GA, Ngocho JS, Knettel BA, Oshosen M, Mmbaga BT, Watt MH. “At
425 home, no one knows”: A qualitative study of retention challenges among women living
426 with HIV in Tanzania. Plos one. 2020;15(8):e0238232.

- 427 25. Mkopi A, Range N, Lwilla F, Egwaga S, Schulze A, Geubbels E, et al. Adherence
428 to tuberculosis therapy among patients receiving home-based directly observed treatment:
429 evidence from the United Republic of Tanzania. *PloS one*. 2012;7(12):e51828.
- 430 26. Mkopi A, Range N, Amuri M, Geubbels E, Lwilla F, Egwaga S, et al. Health
431 workers' performance in the implementation of Patient Centred Tuberculosis Treatment
432 (PCT) strategy under programmatic conditions in Tanzania: a cross-sectional study. *BMC*
433 *health services research*. 2013;13(1):1-7.
- 434 27. Atanga PN. Retention-in-care, adherence and treatment outcomes in a cohort of
435 HIVpositive pregnant and breastfeeding women enrolled in a pilot project implementing
436 "Option B+" in Cameroon: *Imu*; 2017.
- 437 28. Atanga PN, Ndetan HT, Achidi EA, Meriki HD, Hoelscher M, Kroidl A. Retention
438 in care and reasons for discontinuation of lifelong antiretroviral therapy in a cohort of
439 Cameroonian pregnant and breastfeeding HIV-positive women initiating 'Option B+' in the
440 South West Region. *Tropical Medicine & International Health*. 2017;22(2):161-70.
- 441
- 442